about
Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.Design, synthesis, and biological evaluation of scaffold-based tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4).Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations.Diastereoselective reduction of a chiral N-Boc-protected delta-amino-alpha,beta-unsaturated gamma-keto ester Phe-Gly dipeptidomimetic.Inhibition of HIV fusion by small molecule agonists through efficacy-engineering of CXCR4.Experimental determination of drug diffusion coefficients in unstirred aqueous environments by temporally resolved concentration measurements.Influence of chain length on the activity of tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4).Conformational restrictions in ligand binding to the human intestinal di-/tripeptide transporter: implications for design of hPEPT1 targeted prodrugsDevelopment of a QSAR Model for Binding of Tripeptides and Tripeptidomimetics to the Human Intestinal Di-/Tripeptide Transporter hPEPT1Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, and biological investigationsA minimalistic 3D pharmacophore model for cyclopentapeptide CXCR4 antagonistsProbing the Molecular Interactions between CXC Chemokine Receptor 4 (CXCR4) and an Arginine-Based Tripeptidomimetic Antagonist (KRH-1636)Structure-activity relationship studies of the aromatic positions in cyclopentapeptide CXCR4 antagonistsRational design of conformationally constrained cyclopentapeptide antagonists for C-x-C chemokine receptor 4 (CXCR4)
P50
Q34294663-D7BB32E0-BB1F-496A-BB2F-160B63919113Q38542935-65350D11-AEAD-4A49-9B31-1F44A5CDA5FBQ39150159-040B50F1-89B4-419D-B81B-0BD80C744835Q39157622-259E6363-9AAB-401D-B240-A6430B3065D7Q40592833-BF650207-685B-4E55-AD65-0A98ED407ECBQ44256012-E8A796FC-6ADE-444E-9401-D3B6D5793B25Q49817266-45F17CA4-A696-4FE0-8379-372047309416Q50026460-637FB5B2-1293-4FB2-8BE0-BD046242C252Q51275350-036D5CA7-2A97-4045-BDAD-109B9EAD4A90Q61621851-AD1CE592-77BA-4D03-B45F-6BDC41A700B4Q62648677-0EF37930-92E1-4C25-B1C6-AD90B979AE4CQ80515413-6F262B9F-D58B-4CE2-94AA-2F77DB1A2FDDQ82907748-B8EFC8AA-D75C-4836-B4A1-0912C9980055Q86226678-D7F85163-E28B-4D26-8C47-823E0814AF71Q86573459-A5645CC1-4E1A-468A-80A9-8353A42D16E6Q87416452-6612B6A2-0F6E-4813-851E-20E381C59B46
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jon Våbenø
@ast
Jon Våbenø
@en
Jon Våbenø
@es
Jon Våbenø
@nl
type
label
Jon Våbenø
@ast
Jon Våbenø
@en
Jon Våbenø
@es
Jon Våbenø
@nl
prefLabel
Jon Våbenø
@ast
Jon Våbenø
@en
Jon Våbenø
@es
Jon Våbenø
@nl
P106
P31
P496
0000-0003-0918-1066